PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells - Wikidata - wikimedia - TriplyDB

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells

http://www.wikidata.org/entity/Q24654958

about

PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Paradoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphoma Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.RuvBL2 is involved in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells.Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2.The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner Targeting Histone Deacetylases in Diseases: Where Are We?Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines.Bortezomib for the treatment of non-Hodgkin's lymphoma The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma Proteasomal regulation of caspase-8 in cancer cell apoptosis High Glucose-Induced Oxidative Stress Mediates Apoptosis and Extracellular Matrix Metabolic Imbalances Possibly via p38 MAPK Activation in Rat Nucleus Pulposus Cells.Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects Caspase control: protagonists of cancer cell apoptosis.HDAC inhibitor-based therapies: can we interpret the code?Therapeutic targeting of cancer cell cycle using proteasome inhibitors Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.CD30 as a therapeutic target for lymphoma.Emerging drugs for diffuse large B-cell lymphoma.Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches.Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL).ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL.HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.

P2860

Q21328686-B3B7CD7A-36CF-4BFF-AA05-2D8CD5104774 Q28082536-2C9CDE39-93C4-4994-8FF3-311DA4BA0F38 Q28535447-214B98F2-5706-49AD-A8FE-2F58F8B31DA9 Q30936712-17761BFA-96B1-43F8-8E04-5932DA00D3D3 Q33391725-A5C4C0D5-0178-4928-953C-21E0EFC6193C Q33896749-672A107E-4F7C-4387-AF45-F40154F1C4B0 Q33983255-AB400B95-9D08-4020-B2E2-6ADC4D8B217A Q34008663-81B41DF8-BEC6-49BA-8EC0-08034B19DABE Q34134986-DA168734-8D11-486C-A02C-A1F5FEA167C5 Q34703660-014AC447-9AAB-493F-B4BF-3D6DE1EB21F6 Q34707183-B0FC2395-1533-4412-91E5-9A6E6CA0C7F2 Q34971840-D6427ABE-0041-49F5-BD4F-D4F9A9E1A2CF Q35089766-3ABF8E0C-F3B2-45F6-8E4E-FD0546DAFAAD Q35206717-0A036581-FF39-4161-A618-5AD5760F75FF Q35337908-27DEB4C0-ED28-45FA-88B3-01891EE8D471 Q35592352-F5F096D0-B296-47CC-97E9-767E50B26342 Q35779961-8D6A6A97-8D8E-4714-A06E-1615D0E00E94 Q35821728-AE77E17D-D709-4445-868D-0A4EC5EEBC2C Q35998436-E0505968-D2C9-4D08-BECC-4635BCC4B750 Q36810416-2380535D-4EFA-4D29-AF05-AFE31AC9C2BE Q36868056-E61016DB-C312-461C-9671-D68F5F2572B9 Q37140809-8CEBF0F3-ADA1-4CF9-B4F3-ABC5B0484885 Q37146270-DF72A8E5-9D15-4168-9AEF-863C9BB4B05F Q37231720-A87E3F11-4F8D-4155-B3EB-62617B318A91 Q37774667-0422B7CB-F9BA-4E5B-9D40-3DB2AD0DBBCA Q37902054-FE05185C-8317-465A-877C-436856C8624B Q37948056-26EE28CF-4FCB-4CD5-A109-AD46E7CC8C54 Q38052382-D7523002-0012-4926-A2CC-053411F28DFA Q38058971-2642D3D2-DB2B-4EC1-898C-893E56FE566D Q38069898-2B0976E2-C365-4EDA-95F4-0E6A20F947EE Q38132359-21D899DD-0E01-4338-B67A-3FCB141F6A6A Q38138482-5FF419FC-757F-47E2-8033-00FFFA32D39E Q38344404-FD997F15-67D8-4ABA-A53D-EF806E3326B8 Q38512046-DBAA77E6-00C8-4096-A989-A068A6BCB546 Q38645501-8C933A65-AFF2-4F18-80DD-5FBA17793A3F Q38801065-284296B4-CA8A-40AD-91BD-0D86E96ACE40 Q38891225-97D3D074-FF8C-4F23-AC80-5366D393D52C Q39021652-5FEFA345-A81B-4A67-9EA2-1DCE7D561246 Q39431594-2EBDCB14-121E-4E05-A9B8-0C5CDDDEDFBA Q39525805-CDE4B702-0E66-43A5-92EE-6D836562E3EC

P2860

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells

http://www.wikidata.org/entity/Q24654958

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

PCI-24781 induces caspase and ...... h bortezomib in lymphoma cells

@ast

PCI-24781 induces caspase and ...... h bortezomib in lymphoma cells

@en

PCI-24781 induces caspase and ...... h bortezomib in lymphoma cells

@nl

type

label

PCI-24781 induces caspase and ...... h bortezomib in lymphoma cells

@ast

PCI-24781 induces caspase and ...... h bortezomib in lymphoma cells

@en

PCI-24781 induces caspase and ...... h bortezomib in lymphoma cells

@nl

prefLabel

PCI-24781 induces caspase and ...... h bortezomib in lymphoma cells

@ast

PCI-24781 induces caspase and ...... h bortezomib in lymphoma cells

@en

PCI-24781 induces caspase and ...... h bortezomib in lymphoma cells

@nl

P1433

Q24654958-4334B55F-4315-4BA3-9E04-F579BB454541

P1476

Q24654958-285AE4B3-380A-400A-9AC6-A02203418783

P2093

Q24654958-22DE08BD-8D1E-4C9C-A32B-CA76F7B1F937

Q24654958-30173C0F-DF96-4FBD-98D0-B18CA62716A6

Q24654958-5A2E5224-46CB-49D5-A1D6-18B619854A3B

Q24654958-8F500A8E-65D2-4FDC-9500-AB8EA9E4E1D3

Q24654958-B0D38512-F03D-41A0-9E25-09E33A369C62

Q24654958-B3319186-CE59-481B-9D01-83AD6EAB829D

Q24654958-BD593E92-AB2F-4E1C-82E8-F48F929ECDC9

Q24654958-DD5B8B39-FF59-4057-9ACC-F94A46BEF011

Q24654958-E67C2958-499C-4ED2-8636-553123081EFA

Q24654958-F5AC7A61-EE86-42F4-9B0F-7F59AFF7955A

P2860

Q24654958-0A5D0636-A6F4-494B-B0B3-961E12F4EA60

Q24654958-0C4FB45E-4EF3-40B3-AC2D-271CD8A91949

Q24654958-1212CD88-9EA1-4457-B727-94C79E829E2A

Q24654958-12758116-8226-4F3C-90BE-6BD3942D7C9A

Q24654958-146368E9-3981-4B72-8314-68973123465F

Q24654958-14A19F68-48BB-440B-B43D-C7120BA1BB2B

Q24654958-1B3985F5-21F6-4D9B-9B45-3522B29D93C0

Q24654958-1B9744AA-E6D7-4E64-AE63-CE6576459D77

Q24654958-3650E3F0-8203-46E5-820E-DEC59BE0F764

Q24654958-3856C0A0-9A31-4929-B6F0-69FDDF605465

P304

Q24654958-D948EAE9-68F7-4C23-91B3-5AB6B50151C3

P31

Q24654958-619134D3-2205-43E4-88C8-D5DB0F4F280A

P3181

Q24654958-74D7A8C4-69EF-4B9E-A7E4-4642B41B547E

P356

Q24654958-767224EA-CF8D-46CB-A64D-9AEDB400A5EF

P407

Q24654958-73800012-A736-48EF-B555-C8CFB29025D8

P433

Q24654958-F76E65A5-7084-4189-85BA-E1E8B59226A6

P478

Q24654958-093B74BA-B96B-4107-A8B7-E0077CB1E2B6

P577

Q24654958-2B269E2F-F678-4B1E-A35E-E9843EA50D3F

P698

Q24654958-825B9899-C949-420E-A9D5-B0A12F0D9A0F

P921

Q24654958-4589092A-695E-4B2C-BB7E-8AA03E81786C

P932

Q24654958-B206ECFE-AD9A-412A-A063-A9E2BECBE7EA

P3181

P356

1078-0432.CCR-08-2365

P1433

Clinical Cancer Research

P1476

PCI-24781 induces caspase and ...... h bortezomib in lymphoma cells

@en

P2093

Andrew M Evens

http://www.w3.org/2001/XMLSchema#string

Joseph Buggy

http://www.w3.org/2001/XMLSchema#string

Kevin David

http://www.w3.org/2001/XMLSchema#string

Lauren Mauro

http://www.w3.org/2001/XMLSchema#string

Leo I Gordon

http://www.w3.org/2001/XMLSchema#string

Mint Sirisawad

http://www.w3.org/2001/XMLSchema#string

Richard Miller

http://www.w3.org/2001/XMLSchema#string

Savita Bhalla

http://www.w3.org/2001/XMLSchema#string

Sheila Prachand

http://www.w3.org/2001/XMLSchema#string

Sriram Balasubramanian

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

Epigenetics in human disease and prospects for epigenetic therapy

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

NF-kappaB in cancer: from innocent bystander to major culprit

Gene silencing in cancer in association with promoter hypermethylation

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.

P304

3354-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2250594

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-08-2365

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19417023

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

2704489

http://www.w3.org/2001/XMLSchema#string